NEW YORK, July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is inves

Viking Therapeutics just launched its next-gen weight loss program. Novo Nordisk and Eli Lilly are a

The key trial results for VK2735 are still years away. There are some useful indicative results comi

The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $37.08, representing a +1.95

VKTX's Q2 report could hinge on VK2735 pipeline updates as investors await progress on obesity studi

NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is i

Viking Therapeutics, Inc. (VKTX) reached $36.37 at the closing of the latest trading day, reflecting

Viking Therapeutics, Inc. (VKTX) reached $38.86 at the closing of the latest trading day, reflecting

Viking Therapeutics (NASDAQ:VKTX) has outperformed the market over the past 10 years by 26.85% on an

Viking Therapeutics is advancing its GLP-1 weight-loss pipeline, with Phase 3 trials progressing and

Viking Therapeutics continues to strengthen within a long-term bottoming pattern, but a pullback or

Viking Therapeutics (VKTX +2.28%) may be one of biotech's most tempting buyout targets, thanks to it

Viking Therapeutics' expanding obesity pipeline and upcoming VK2735 data reignite buyout speculation

The GLP-1 trade has matured from a single-stock story into a tiered opportunity set.

Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $39.97, moving 5.13% from the

A deepening sell-off in chip and memory stocks dragged all four major U.S. equity indexes lower by m

A deepening chipmaker slide pulls all major U.S. indexes lower Tuesday while oil climbs on a Strait

CRISPR Therapeutics AG has successfully launched Casgevy, the first FDA-approved CRISPR-based gene t

CRISPR Therapeutics has transitioned to the commercial stage with the first approved CRISPR-based ge

The weight-loss market is crowded, but this company's lead drug candidate has several key advantages

Viking Therapeutics could have a medicine on the market within two years. To capture market share, t

Viking Therapeutics launches Phase 1 trial for obesity drug VK3019, a dual amylin/calcitonin recepto

Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical compa

A global semiconductor sell-off hammered the Nasdaq on Tuesday, but a rotation into defensives and s

U.S. stocks sank Monday as an Iranian drone attack on a UAE petroleum site sent Brent above $114, go

U.S. equities fell broadly Wednesday as Brent Crude surged past $108 on reports of Iranian energy-fa

Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quart

Gainers

  During Monday's trading, 1214 companies set new 52-week lows.

  During Thursday, 849 stocks hit new 52-week lows.

  On Friday, 431 companies hit new 52-week lows.

Stocks That Hit 52-Week Lows On Monday

Stocks That Hit 52-Week Lows On Thursday

Stocks That Hit 52-Week Lows On Thursday